Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : WASP -- Ignore unavailable to you. Want to Upgrade?

To: SteelerStu who wrote (4)	4/18/1999 4:05:00 PM
From: hdrider	Read Replies (3) \| Respond to of 193

Agree This company keeps coming with news. I see the stock at a base of 5 in the near future. If acne drug is as good as they say it will really turn this company around.

To: SteelerStu who wrote (4)	9/21/1999 2:25:00 PM
From: Jeffrey L. Henken	Read Replies (1) \| Respond to of 193

Wasatch Pharmaceutical Announces Foreign and Domestic Licensing MIDVALE, Utah--(BUSINESS WIRE)--Aug. 11, 1999--As previously announced, Wasatch (OTC BB:WASP) has begun the application process with the FDA for over-the-counter approvals on seven of its products. After an update from FDA regulators, it is anticipated that approvals could come within the next twelve to fourteen months. With a focus on the U.S. domestic market, Wasatch has not overtly pursued foreign licensing. We are pleased to announce that this policy will change as a result of requests from medical and retail entities having a strong presence in Brazil, New Zealand and Australia. With existing ancillary products, soaps and skin moisturizers, Wasatch is in a position to make these superior products available to the general public in these countries and the US market. No FDA approvals are needed for over-the-counter use of these products. Therefore, licensing in these countries and the US will be actively nurtured with existing contacts for products that are ready for market. With a less than one percent sensitivity reaction to these products, the general public will be able to have access to these products previously available only to patients in medical clinics owned by Wasatch Pharmaceutical. These products will be a welcome relief to those in the general population who cannot use existing over-the-counter soaps and creams. Licensing agreements for these products will prove to be a strong source of revenue to Wasatch. And with FDA approvals anticipated on the seven other OTC products, we feel licensing of products will play a major role in our overall presence in the OTC market. NOTE: Any statements released by Wasatch Pharmaceutical Inc. that are not strictly historical are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Editors and investors are cautioned that forward-looking statements invoke risk and uncertainties that may affect the companys business prospects and performance. These include economic, competitive, governmental, technological and other factors discussed in the companys filings with the Securities and Exchange Commission. Contact: Wasatch Pharmaceutical Inc., Midvale Gary Heesch, 801/272-1709